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LEDGF/p75 binding-defective IN mutant viruses were previously characterized as replication-defective, yet RNAi did not reveal an essential
role for the host factor in HIV-1 replication. Correlative analyses of protein binding and viral fitness were expanded here by targeting 12 residues
at the IN-LEDGF/p75 binding interface. Whereas many of the resultant viruses were defective, the majority of the INs displayed wild-type in vitro
integration activities. Though an overall trend of parallel loss of LEDGF/p75 binding and HIV-1 infectivity was observed, a strict correlation was
not. His-tagged INA128Q, derived from a phenotypically wild-type virus, failed to pull-down LEDGF/p75, but INA128Q was effectively recovered
in a reciprocal GST pull-down assay. Under these conditions, INH171A, also derived from a phenotypically wild-type virus, interacted less
efficiently than a previously described interaction-defective mutant, INQ168A. Thus, the relative affinity of the in vitro IN-LEDGF/p75 interaction
is not a universal predictor of IN mutant viral fitness.
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Following entry into a target cell, the retroviral enzyme
reverse transcriptase (RT) synthesizes linear double-stranded
cDNA containing a copy of the viral long terminal repeat (LTR)
at each end. The integration of this cDNA into a cell
chromosome is an essential step in the retroviral lifecycle. The⁎ Corresponding authors. Peter Cherepanov is to be contacted at Division of
Medicine, Imperial College London, St. Mary's Campus, Norfolk Place,
London, W2 1PG, UK. Fax: +44 20 7594 3906. Alan Engelman, Department of
Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney Street,
Boston, MA 02115, USA. Fax: +1 617 632 3113.
E-mail addresses: p.cherepanov@imperial.ac.uk (P. Cherepanov),
alan_engelman@dfci.harvard.edu (A. Engelman).
1 These authors contributed equally to this work.
2 Present address: Infectious Disease Division, Massachusetts General
Hospital, 65 Landsdowne St., Cambridge, MA 02139, USA.
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.08.011viral integrase (IN) recognizes specific nucleotide sequences at
the LTR ends, and catalyzes 3′ processing wherein a dinu-
cleotide is most often removed from each end. In the nucleus, IN
uses the 3′-OH groups of the recessed LTR termini to attack a
pair of phosphodiester bonds on opposite strands of a DNA
target, which concomitantly joins the viral 3′ ends to the
chromosome. Host cell enzymes repair the single-strand gaps in
the resulting DNA strand transfer intermediate during the final
phase of the integration process. Integration occurs within the
context of a large nucleoprotein structure termed the preintegra-
tion complex (PIC) that consists of the viral cDNA and a number
of viral and cellular proteins. See Craigie (2002) for a detailed
overview of retroviral DNA integration.
Purified human immunodeficiency virus type 1 (HIV-1) IN is
sufficient to process and integrate recombinant DNA substrates
in vitro that mimic the viral cDNA ends (Bushman et al., 1990;
Sinha and Grandgenett, 2005). Yet there is growing evidence
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human pathogen in cells. Potential HIV-1 integration co-factors
can be divided into two groups based on whether they interact
directly with IN. Some, like the barrier-to-autointegration factor
(BAF) and high mobility group protein A1 (HMGA1), appear to
associate with PICs primarily through their affinities for DNA
(Harris and Engelman, 2000; Hindmarsh et al., 1999; Li et al.,
2000; Mansharamani et al., 2003). Others, such as IN-interactor
1 (Kalpana et al., 1994), lens epithelium-derived growth factor
(LEDGF)/p75 (Cherepanov et al., 2003; Emiliani et al., 2005;
Turlure et al., 2004), hepatoma-derived growth factor related
protein 2 (HRP2) (Cherepanov et al., 2004), and histone
acetyltransferase p300 (Cereseto et al., 2005), bind directly to
IN.
LEDGF/p75 appears to be the dominant cellular binding
partner of HIV-1 IN. Ectopically expressed IN localizes to cell
nuclei (Petit et al., 1999; Pluymers et al., 1999) and interacts
tightly with condensed chromosomes (Cherepanov et al., 2000;
Devroe et al., 2003). Each of these properties depends upon its
interaction with LEDGF/p75, as RNA interference (RNAi)
knockdown of endogenous LEDGF/p75 redistributed IN from
the nucleus to the cytoplasm and depleted the viral factor from
mitotic chromosomes (Llano et al., 2004; Maertens et al., 2003).
Consistent with these observations, binding to LEDGF/p75
mediates the cytoplasmic and nuclear dynamics of ectopically
expressed HIV-1 IN (Maertens et al., 2005). Furthermore,
interaction-defective mutants INQ168A and INQ168L failed to
effectively engage condensed chromosomes (Emiliani et al.,
2005).
The importance of the IN-LEDGF/p75 interaction for HIV-1
replication has been studied using host and viral genetic
approaches, with some conflicting results. RNAi depletion of
LEDGF/p75 in 293Tor Jurkat cells failed to reveal a measurable
reduction in HIV-1 titers (Llano et al., 2004). Two to threefold
less infectivity was observed following LEDGF/p75 depletion in
HeLa-P4 cells (Vandegraaff et al., 2006). Due to a concomitant
reduction in cell proliferation noted in this study, the infectivity
defect was not clearly attributable to the loss of LEDGF/p75
protein (Vandegraaff et al., 2006). However, rescue of infectivity
upon expression of RNAi-resistant forms of LEDGF/p75 cDNA
in HeLa-P4 cells was reported in an independent study,
suggesting that the cell factor does play an important role in
HIV-1 replication (Vandekerckhove et al., 2006). Since LEDGF/
p75 is an abundant nuclear protein, with an estimated copy
number of 4×105 molecules per cell (Vandegraaff et al., 2006), it
seems plausible that RNAimight reduce protein concentration to
a threshold level, where HIV-1 replication defects can just be
seen.
Lentiviruses tend to integrate into active transcription units
under conditions where the Gammaretrovirus Moloney murine
leukemia virus (Mo-MLV) or Alpharetrovirus avian sarcoma-
leukosis virus (ASLV) target genes less so (Mitchell et al., 2004;
Narezkina et al., 2004; Schroder et al., 2002; Wu et al., 2003).
The interaction with LEDGF/p75 appears to be specific for
lentiviruses (Busschots et al., 2005; Llano et al., 2004) and was
hypothesized to account for the bias towards integration into
transcription units (Bushman, 2003; Engelman, 2005; Maertenset al., 2003). Indeed, cells depleted for LEDGF/p75 supported
less HIV-1 integration into active genes as well as A/T-rich
DNA sequences (Ciuffi et al., 2005). As LEDGF/p75 contains
two AT-hook motifs which in part mediate its binding to DNA
and chromatin (Turlure et al., 2006), LEDGF/p75 may directly
tether HIV-1 PICs to human chromatin during integration.
Viral genetic analyses have also hinted at a potentially
important role for LEDGF/p75 in HIV-1 replication. The
following missense mutations (i) disrupt the protein–protein
interaction in vitro without abrogating IN catalytic function
and (ii) impart potent integration/preintegration blocks in
infected cells: H12N (Engelman and Craigie, 1992; Engelman
et al., 1995; Maertens et al., 2003), V165A (Bouyac-Bertoia
et al., 2001; Cherepanov et al., 2005b; Lu et al., 2004;
Turlure et al., 2004), R166A (Bouyac-Bertoia et al., 2001;
Cherepanov et al., 2005b; Wiskerchen and Muesing, 1995),
L172A/K173A (Cherepanov et al., 2005b; Priet et al., 2003),
Q168A, and Q168L (Emiliani et al., 2005). These genetic
data seem to indicate that the IN-LEDGF/p75 interaction
could play an essential role in HIV-1 replication. To put this
hypothesis to a more rigorous test and further explore the
functional significance of residues in IN that form the
LEDGF/p75 binding interface, we have targeted additional
points of contact revealed in the recent co-crystal structure of
the LEDGF/p75 IN-binding domain (IBD) bound to the IN
catalytic core domain (CCD) (Cherepanov et al., 2005a). We
characterized the resulting mutant INs for 3′ processing, DNA
strand transfer, and binding to LEDGF/p75 together with the
infectivities of the corresponding mutant viruses. From these
analyses, we conclude that the affinity of mutant viral IN for
LEDGF/p75 protein in vitro falls short of a universal predictor
for the replication capacity of the corresponding mutant virus.
Results
Mutagenesis strategy
We recently reported a crystal structure of the complex
between the LEDGF/p75 IBD and HIV-1 IN CCD, which
revealed IBD interhelical loop residues Ile-365 and Asp-366
buried in a pocket formed at the CCD dimer interface
(Cherepanov et al., 2005a). Helices α1 and α3 from one of
the IN monomers (chain B or the leftward protomer as depicted
in Fig. 1) together with α5 and a short stretch of residues (amino
acids 168–171) that connects α4 to α5 in the other IN
monomer, were primarily responsible for recognizing LEDGF/
p75 (Fig. 1).
Previous work defined LEDGF/p75 amino acids Ile-365,
Asp-366, and Phe-406 as hotspot residues because their
alterations abrogated binding to IN in an in vitro Ni2+-
nitrilotriacetic acid (Ni-NTA) pull-down assay (Cherepanov
et al., 2005b). The crystal structure was instrumental in under-
standing the molecular basis for these observations. Thus, Asp-
366 is involved in a bidentate hydrogen (H) bond with the
backbone amides of IN residues Glu-170 and His-171 (Fig. 1).
The Ile-365 side-chain is buried within a hydrophobic pocket
formed by IN residues Leu-102, Ala-128, Ala-129, Trp-132,
Fig. 1. The IBD-CCD structure and selection of amino acids for mutagenesis. Stereo view (Protein Data Bank code 2B4J) of the protein interface (amino acid residues
highlighted as sticks). Chain A of the IN dimer, shown at the right, is colored blue; chain B, green; and chain C (the LEDGF/p75 IBD), violet. See text for additional
details.
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contacts with IN residue Trp-131 (Cherepanov et al., 2005a)
(Fig. 1).
IN mutations V165A, R166A, L172A/K173A (Cherepanov
et al., 2005b), Q168L, or Q168A (Emiliani et al., 2005) (Fig. 1,
rightward blue protomer) impaired binding to LEDGF/p75 in
vitro. Importantly, these changes precluded viral integration,
although the corresponding IN proteins retained full or partial in
vitro enzymatic activities (Table 1). INV165A and INL172A/K173A
also efficiently functioned in infected cells when assayed in
trans to IN active site mutant viruses as Vpr-IN fusion proteins
(Bouyac-Bertoia et al., 2001; Lu et al., 2004; Priet et al.,Table 1
Targeted amino acid residues
Residue Conservation a Activity b Infectiv
Glu-69 99.7 na d E69A/K
Ala-128 99.4 A128E/A129W/C130L (down) na
Ala-129 99.4 A128E/A129W/C130L (down) na
Trp-131 100 W131E (active) na
W131D/F139D/F185K (100)
Trp-132 100 na na
Val-165 91.8 V165A (14–45) V165A
V165A (100) e V165A
Arg-166 99.1 R166A (100) e R166A
R166A
Asp-167 75.1 na D167A
Gln-168 99.7 Q168A (100) Q168A
Q168L (100) Q168L
His-171 99.1 H171K/L172Q (down) E170A
H171A
Leu-172 99.1 L172A/K173A (100) L172A
a Percent identity at that position among a collection of 342 HIV-1 and SIVcpz str
b Percent wild-type 3′ processing activity for the noted INs. Multiply-mutated enzy
that did not quantify activity, descriptive terms are used instead.
c Percent wild-type infectivity or descriptive phenotype of the noted mutant virus
d na, not applicable.
e Disintegration activity.
f INL172A/K173A was analyzed because the relative insolubility of INL172A preclude2003). Here, seven additional residues that help to mold the
LEDGF/p75 binding pocket, and distribute to both chains of
the IN dimer, were targeted by site-directed mutagenesis. Thus,
His-171 was altered because its backbone amide is contacted by
Asp-366, and the well-conserved imidazole side-chain helps to
form the base of the binding pocket (Fig. 1). As Glu-69 interacts
with Arg-166 through a salt-bridge (Fig. 1), it was targeted to
test the role of this intramolecular interaction in LEDGF/p75
recognition and IN function. Asp-167 was targeted because this
solvent-accessible side-chain extends towards LEDGF/p75
residue Lys-360, potentially forming a salt-bridge (Fig. 1).
Trp-131 and Trp-132 were targeted because of the notedity c References Mutants
71A (<0.006) Wiskerchen and Muesing (1995) E69R
Chen et al. (2006) A128Q
Chen et al. (2006) A129Q
Goldgur et al. (1998) W131D
Wang et al. (2001)
W132A
(<0.01) Lu et al. (2004) V165A
(0.2–0.3) Bouyac-Bertoia et al. (2001)
(0.2–0.4) Bouyac-Bertoia et al. (2001) R166A
(0.37) Wiskerchen and Muesing (1995)
(53) Wiskerchen and Muesing (1995) D167A
D167K
(dead) Emiliani et al. (2005) Q168A
(dead) Emiliani et al. (2005) Q168L
/H171A (30) Chen et al. (2006) H171A
/K173A (29) Wiskerchen and Muesing (1995)
/K173A (dead) Priet et al. (2003, 2005) L172A
L172A/K173A f
ains (http://www.hiv1.lanl.gov).
mes are indicated if single amino acid substitutions were not studied. For studies
es.
d its purification from the soluble fraction.
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Phe-406. In addition, surface-exposed Trp-131 was the only
CCD residue that underwent significant rearrangement upon
formation of the IN-LEDGF/p75 complex (Cherepanov et al.,
2005a). A128Q and A129Q were made to potentially interfere
with LEDGF/p75 binding by situating the relatively bulky
Gln side-chain nearby Ile-365 (Fig. 1). Eight new IN mutant
viruses and proteins were constructed through the targeting of
these 7 residues, and each was tested alongside previously
characterized interaction-defective mutants V165A, R166A,
Q168L, Q168A, and L172A (Table 1). Table 1 lists the
conservation of each targeted residue among a large collection
of HIV-1/SIVcpz strains, as well as previous studies that may
have analyzed the roles of these residues in IN and HIV-1
function.
Mutant virus analyses
Initially, the mutations in IN were characterized for their
affects on HIV-1 infectivity. Integration is essential for HIV-1
replication, and a number of IN mutations, such as those that
alter the Asp and Glu residues of the D,D-35-E catalytic triad,
abrogate HIV-1 replication specifically at the integration step.
Yet many if not most IN mutations exert pleiotropic effects on
the HIV-1 lifecycle, affecting reverse transcription and/or
particle assembly and release in addition to integration. IN
mutations that block replication uniquely at the integration step
are called class I to distinguish them from the class II mutations
that exert additional pleiotropic effects (reviewed in Engelman,
1999).
Virus assembly/release
To assess the post-integration phenotypes of IN mutant
viruses, HeLa cells were transfected with full-length molecular
clones. This assay is well suited for quantifying assembly and
release effects since it bypasses integration as a requirement for
gene expression. CD4-negative HeLa cells also permit the
comparison of replication-competent and replication-defective
strains in the absence of HIV-1 spread. The majority of the IN
mutant viruses were released at or near the level of wild-type
HIV-1NL4-3 (at most 2.5-fold defective, Fig. 2A). As previously
reported (Lu et al., 2004), HIV-1R166A displayed reduced
particle production, to about 15% of the wild-type level (Fig.
2A). Three of the novel mutant viruses, HIV-1A129Q, HIV-
1W131D, and HIV-1W132A, displayed even more severe defects,
yielding approximately 5 to 12% of wild-type activity in
repeated experiments (Fig. 2A).
Single-round infectivity
The infectivity of each mutant was analyzed in a single-
round assay utilizing reporter viruses carrying the gene for
firefly luciferase to facilitate quantitative readout. This design is
well suited for assessing mutational affects on the early steps of
the HIV-1 lifecycle, as IN catalytic mutants support approxi-
mately 0.05 to 0.1% of wild-type activity under these conditions
(Lu et al., 2004; 2005a, 2005b). To account for the different
efficiencies at which some of the mutants were released fromtransfected cells, viral supernatants were normalized for RT
content prior to infection.
The infectivities of previously characterized LEDGF/p75
interaction-defective mutants HIV-1V165A.Luc(R−) and HIV-
1R166A.Luc(R−) were below the detection limit of the assay
(<0.01% of wild-type infectivity; Fig. 2B). HIV-1Q168L.Luc(R−)
and HIV-1Q168A.Luc(R−), whose IN proteins were reportedly
deficient for binding to LEDGF/p75 (Emiliani et al., 2005),
supported 0.6±0.1% and 0.8±0.1% of wild-type activity,
respectively. HIV-1L172A.Luc(R−) likewise supported 0.8±0.3%
relative infectivity (Fig. 2B).
Importantly, the novel IN mutant viruses displayed a
wide range of infectivity phenotypes. HIV-1E69R.Luc(R−),
HIV-1A129Q.Luc(R−), and HIV-1W132A.Luc(R−) scored below the
detection limit of the assay. In stark contrast, HIV-1A128Q.Luc(R−),
HIV-1D167A.Luc(R−), and HIV-1H171A.Luc(R−) behaved similar
to the wild-type, supporting 95±29%, 140±12%, and 90±
21% of wild-type activity, respectively (Fig. 2B). Two of the
mutants, HIV-1W131D.Luc(R−) and HIV-1D167K.Luc(R−), sup-
ported the intermediary infectivities of 24±2.5% and 5.7±
0.1%, respectively (Fig. 2B).
DNA synthesis
To complete the phenotypic characterization of IN mutant
viruses, reverse transcription levels were determined by
utilizing real-time quantitative (RQ) PCR. As the retroviral
integration substrate is linear double-stranded cDNA, Taqman
primers and probes were selected to detect late reverse
transcription (LRT) products that require the second template
switch of reverse transcription for their formation (Butler et al.,
2001; Julias et al., 2001; Zack et al., 1990). Cells were lysed at
7 h post-infection (hpi), the approximate peak of LRT formation
under these conditions of HIV-1 infection (Chen et al., 1999;
Kim et al., 1989; Lu et al., 2004).
Most of the IN mutant viruses, with the exception of
HIV-1H171A.Luc(R−), synthesized less DNA than wild-type
HIV-1NLX.Luc(R−) (Fig. 2C). The other two viruses that displayed
wild-type behavior in the infection assay, HIV-1A128Q.Luc(R−)
and HIV-1D167A.Luc(R−) (Fig. 2B), displayed modest (about 2-
to 2.5-fold) DNA synthesis defects (Fig. 2C). Levels of
HIV-1W131D.Luc(R−) and HIV-1D167K.Luc(R−) reverse transcrip-
tion were noticeably less, roughly mirroring the relative infec-
tivities of these mutant viruses (compare panel C to panel B).
Less infectious mutant viruses fell into two categories:
HIV-1E69R.Luc(R−), HIV-1R166A.Luc(R−), and HIV-1Q168A.Luc(R−)
displayed approximate 2.5- to 4-fold DNA synthesis
defects, whereas HIV-1A129Q.Luc(R−), HIV-1W132A.Luc(R−),
HIV-1V165A.Luc(R−), HIV-1Q168L.Luc(R−), and HIV-1L172A.Luc(R−)
were five to approximately 15-fold defective in repeat experi-
ments (Fig. 2C). Of note, previous studies reported similar
reverse transcription defects for HIV-1V165A (Lu et al., 2004;
2005a) and HIV-1L172A (Priet et al., 2005). Table 2 summarizes
the assembly/release, infectivity, and reverse transcription
phenotypes of the different mutant viruses.
RQ-PCR determination of 2-LTR circle levels at 24 hpi,
which can be used to gauge the efficiency of virus entry into the
nucleus (Brown et al., 1987; Lu et al., 2004), revealed normal
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previously reported (Emiliani et al., 2005), HIV-1Q168A.Luc(R−)
and HIV-1Q168L.Luc(R−) converted somewhat less (approximately
two to threefold) of their LRT products to 2-LTR circles in repeat
experiments (data not shown).
Recombinant viral and host factor protein analyses
We next turned to the characterization of recombinant IN
proteins purified from soluble extracts of Escherichia coli cells
using Ni-NTA and heparin sepharose chromatography. Most of
the mutant proteins displayed solubility and purification profiles
similar to INWT, with two notable exceptions. INL172A was
virtually insoluble, precluding its purification from the solublefraction. Thus, the previously characterized double mutant
INL172A/K173A (Cherepanov et al., 2005b; Priet et al., 2003) was
studied instead. Though sufficient INA129Q protein was
extracted to permit purification, its relative insolubility yielded
a product that was noticeably less pure than INWT and the other
mutant proteins (Fig. 3A).
Ni-NTA pull-down
We initially characterized the IN-LEDGF/p75 interaction
using a previously described Ni-NTA pull-down assay
(Cherepanov et al., 2005b; Maertens et al., 2003). As reported,
undetectable levels of LEDGF/p75 were pulled-down in the
absence of added IN-His6, and the majority of the input host
factor (70±5.9%) was recovered in its presence (Fig. 3A, lanes
1–3). The specificity of the assay is highlighted by the lack of
recovery of bovine serum albumin, of which 10 μg was included
in each reaction. As previously demonstrated (Cherepanov et al.,
2005b), the active site mutant protein IND64N also efficiently
pulled-down LEDGF/p75 (about 82% of the level recovered by
INWT; Fig. 3A, lane 4). In contrast, each of INs that carried an
amino acid substitution in the LEDGF/p75 binding pocket
displayed a noticeably weaker affinity for the host factor under
these conditions (Fig. 3A, compare lanes 5–17 to lanes 3 and 4).
Indeed, the only mutants that reproducibly recovered detectable
levels of LEDGF/p75 were INW131D (about 7% of the level of
INWT recovery, lane 8), IND167A (about 25% of INWT recovery,
lane 12), and INH171A (about 5% of the level of INWT recovery,
lane 16). Of note, the viruses harboring these mutations were
either partially (W131D) or near fully (D176A, H171A)
infectious.
Glutathione S-transferase (GST) pull-down and yeast
two-hybrid assays
The results of the previous experiment revealed that a novel
mutant IN, derived from phenotypically wild-type HIV-1A128Q,
failed to pull-down detectable levels of LEDGF/p75 protein
(Fig. 3A, lane 6). Due to this somewhat unexpected finding, the
protein–protein interaction was investigated using a secondFig. 2. Characterization of IN mutant viruses. (A) Virus release profiles.
Supernatants of HeLa cells transfected with the indicated full-length molecular
clones were analyzed for RT activity. Error bars represent the variation obtained
from a duplicate set of transfections, each analyzed in duplicate for RT activity.
Values were normalized to wild-type (WT) HIV-1NL4-3. (B) Mutant viral
infectivities. Values, expressed as percent of wild-type (WT) HIV-1NLX.Luc(R−),
were derived from a duplicate set of infections, each assayed in duplicate for
luciferase activity. As HIV-1W131D.Luc(R−) (underlined) was poorly released from
transfected cells, it was compared to wild-type at 10% of the RT cpm level
utilized for the other viruses. The relative infectivities of HIV-1A128Q.Luc(R−),
HIV-1D167A.Luc(R−), HIV-1D167K.Luc(R−), HIV-1Q168A.Luc(R−), HIV-1Q168L.Luc(R−),
and HIV-1H171A.Luc(R−) at this lower level of virus input were similar to those
obtained at the higher multiplicity of infection. <, luciferase activity below the
detection limit of the assay (<0.01% of wild-type). (C) Reverse transcription
profiles of IN mutant viruses. Jurkat cells infected with the indicated single-
round viruses were harvested at 7 hpi, and normalized levels of LRT products
were determined by RQ-PCR as previously described (Limón et al., 2002; Lu et
al., 2004). Error bars are the variation obtained from duplicate RQ-PCR assays.
Results are representative of those observed from a minimum of two
independent sets of infection and duplicate RQ-PCR assays.
Table 2
Summary of IN mutant viral and enzyme phenotypes






D64N nd f nd nd 96 (<0.1) <1.0
E69R 52 (23) <0.01 36 (8.4) 23 (5.6) 93 (1.6)
A128Q 51 (11) 95 (29) 56 (21) 81 (2.0) 104 (0.5)
A129Q 5.1 (0.1) <0.01 10 (2.5) 11 (6.1) 36 (2.4)
W131D 12 (3.6) 24 (2.5) 13 (11) 83 (7.1) 112 (3.2)
W132A 5.0 (1.3) <0.01 8.1 (1.1) 5.3 (3.2) 4.2 (0.4)
V165A 53 (6.3) <0.01 18 (0.1) 10 (6.6) 72 (30)
R166A 15 (4.1) <0.01 25 (6.2) 10 (8.2) 110 (5.1)
D167A 66 (19) 140 (12) 39 (15) 74 (20) 104 (0.3)
D167K 43 (3.5) 5.7 (0.1) 8.7 (5.7) 54 (30) 104 (1.5)
Q168A 92 (1.3) 0.8 (0.1) 26 (5.2) 62 (26) 101 (7.7)
Q168L 55 (5.0) 0.6 (0.1) 12 (3.1) 22 (8.4) 101 (8.0)
H171A 89 (8.4) 90 (21) 149 (0.3) 49 (21) 108 (3.9)
L172A 58 (12) 0.8 (0.3) 7.5 (<0.1) nd nd
L172A/
K173A
nd nd nd 29 (14) 97 (<0.1)
a Based on results in Fig. 2A. Values in parentheses are variations obtained
from a duplicate set of transfections, each analyzed in duplicate for RT activity.
b Results presented in Fig. 2B. Parenthesized values are variations obtained
from a duplicate set of infections, each assayed in duplicate for luciferase
activity.
c RQ-PCR values at 7 hpi (Fig. 2C). Parenthesized values are variations
obtained from a duplicate set of RQ-PCR assays.
d Results of GST-IBD pull-downs (Fig. 3B). Values in parentheses are
variations obtained from two independent sets of pull-down assays.
e 3′ processing activities (Figs. 4B and C). Parenthesized values are variations
obtained from a duplicate set of enzyme assays.
f nd, not determined.
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LEDGF/p75 including the isolated IBD (GST-IBD) efficiently
pull down INWT (Cherepanov et al., 2004) (Fig. 3B, lane 2).
Thus, the GST-IBD was used as bait to ascertain the relative
affinity of the domain for the different IN mutant proteins. As
expected from the results in panel A, GST-IBD readily co-
precipitated the IND64N active site mutant (Fig. 3B, lane 3).
Under the conditions of the GST pull-down assay, an
interaction between LEDGF/p75 and INA128Q was readily
evident, as GST-IBD pulled down about 54% of the input IN
(81±2.0% of INWT recovery; Fig. 3B, lane 5). Likewise, GST-
IBD co-precipitated IND167A and INH171A (74±20% and
49±21% of INWT recovery, respectively; Fig. 3B, lanes 11 and
15), two other INs that supported the wild-type level of HIV-1
infection. The two INs that supported intermediary infectivities,
INW131D and IND167K, also efficiently co-purified with GST-IBD
(83±7.1% and 54±30% of INWT recovery, respectively; Fig.
3B, lanes 7 and 12). Persuasively, GST-IBD failed to effectively
recover the INs derived from novel noninfectious viruses
HIV-1E69R, HIV-1A129Q, and HIV-1W132A (Fig. 3B, lanes 4, 6,
and 8). Furthermore, the majority of the previously described
interaction-defective mutants, INV165A, INR166A, INQ168L, and
INL172A/K173A, were only inefficiently recovered by GST-IBD
(10±6.6%, 10±8.2%, 22±8.4%, and 29±14% of INWT reco-
very, respectively; Fig. 3B, lanes 9, 10, 14, and 16). A noted
exception was INQ168A. Though this mutant clearly failed to
recover LEDGF/p75 by Ni-NTA pull-down (Fig. 3A, lane
14), GST-IBD bound about 42% of input INQ168A (62±26%of INWT in repeat experiments; Fig. 3B, compare lane 13 to
lane 2). As this was somewhat unexpected (Emiliani et al.,
2005), two additional experiments were performed to further
probe the mechanism of the LEDGF/p75-INQ168A interaction.
First, Asn was substituted for LEDGF/p75 hotspot residue
Asp-366. As this abrogated GST-IBD pull-down of INWT and
INQ168A alike (Fig. 3C, lanes 4, 5, 7, and 8), the IBD
apparently uses the same molecular interactions to recognize
each of the IN proteins. Secondly, a subset of previously
characterized interaction-defective mutants was analyzed using
a yeast two-hybrid interaction assay. The relative binding
affinities of INV165A, INR166A, INQ168A, and INL172A/K173A in
this assay roughly mirrored their percent recoveries in the GST
pull-down assay (compare Figs. 3D to B). Also note that the
D366N substitution effectively abrogated LEDGF/p75's inter-
action with INWT in the yeast two-hybrid assay (Fig. 3D).
IN activities
To ascertain the functionality of the different IN mutant
proteins, 3′ processing and DNA strand transfer activities were
determined using a 21 bp oligonucleotide substrate mimicking
the U5 end of HIV-1 cDNA. With the 5′-end of the cut strand
labeled, 3′ processing yields a radiolabeled 19 nt product (Fig.
4A). IN then inserts the processed DNA into a second
oligonucleotide in the reaction mixture that serves as the target
acceptor for DNA strand transfer (Fig. 4A, bold lines). As
integration occurs essentially anywhere along the target DNA
backbone, strand transfer reaction products are a heterogeneous
population of labeled DNAs whose lengths exceed that of the
starting substrate (Figs. 4A and B).
Reaction products obtained with wild-type and mutant IN
proteins were separated in a denaturing polyacrylamide gel and
quantified (Figs. 4B and C). INWT converted 53±1.3% of the
DNA substrate into the 3′ processing reaction product (Fig. 4B,
lane 2). As expected (Engelman and Craigie, 1992), the D64N
active site mutation inactivated IN function (<1.0% of INWT 3′
processing activity; Fig. 4B, lane 3). In contrast, most of the
LEDGF/p75 binding interface mutant proteins were active,
with the majority, including INE69R, INA128Q, INW131D,
INR166A, IND167A, IND167K, INQ168A, INQ168L, INH171A, and
INL172A/K173A, functioning at or near the level of INWT (Figs.
4B and C). As previously demonstrated (Lu et al., 2004),
INV165A was marginally defective under these assay conditions
(Fig. 4C). Two of the mutant proteins, INA129Q and INW132A,
were noticeably less active. INA129Q supported 36±2.4% of
INWT activity, whereas the activity of INW131A was 4.2±0.4%.
Table 2 summarizes the results of the in vitro pull-down and 3′
processing assays.
Discussion
A variety of host cell factors have been reported to directly
interact with HIV-1 IN and although LEDGF/p75 has received
considerable attention of late (Busschots et al., 2005; Cher-
epanov et al., 2003, 2004, 2005a, 2005b; Ciuffi et al., 2005;
Emiliani et al., 2005; Llano et al., 2004; Maertens et al., 2003;
2005; Turlure et al., 2004; Vandegraaff et al., 2006;
Fig. 3. IN-LEDGF/p75 interaction assays. (A) Ni-NTA pull-down. Lane 1, input LEDGF/p75; lane 2, mock pull-down without IN; lanes 3–17, LEDGF/p75 incubated
with wild-type (WT) IN-His6 or the indicated mutant protein. (B) GST pull-down. Lane 1, mock pull-down without IN; lanes 2–16, GST-IBD pull-down of WTor the
indicated IN mutant. Input IN levels are shown in the lower panel. (C) Specificity of the IBD-INQ168A interaction. Lane 1, input level of INWT; lanes 2 and 3, input
GST-IBD and GST-IBD/D366N, respectively; lanes 4 and 5, GST-IBD and GST-IBD/D366N pull-downs of INWT, respectively; lane 6, input INQ168A; lanes 7 and 8,
GST-IBD and GST-IBD/D366N pull-downs of INQ168A, respectively. The migration positions of molecular mass standards in panels A–C are indicated to the left of
each gel; IN and LEDGF mobilities are at the right. Results are representative of those obtained in a minimum of two independent sets of pull-down assays. (D) Yeast
two-hybrid assay. Relative levels of β-galactosidase activity are shown for each indicated pair of interacting proteins. The scant level of β-galactosidase detected in the
absence of the IBD prey construct defines the background activity of the assay. Error bars represent the variation obtained from four independent transformants of
Y187. LKAA, L172A/K173A.
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awaits further clarification. RNAi studies have yielded mixed
results, suggesting that residual LEDGF/p75 levels might
suffice to confer the wild-type or marginally reduced levels of
virus integration that occurs under these conditions (Llano et al.,
2004; Vandegraaff et al., 2006; Vandekerckhove et al., 2006).
Though LEDGF/p75 plays a role in targeting HIV-1 PICs to
active genes and A/T-rich DNA sequences during integration
(Ciuffi et al., 2005), partial disruption of these processes failed
to negatively impact the replication capacity of the virus (Llano
et al., 2004).
The LEDGF/p75-IN interaction: correlative phenotypes of IN
mutant viruses and enzymes
Previous analyses revealed that viruses carrying mutant INs
that failed to interact with recombinant LEDGF/p75 suffered
catastrophic preintegration blocks in cells (Bouyac-Bertoia
et al., 2001; Cherepanov et al., 2005b; Emiliani et al., 2005;
Engelman et al., 1995; Lu et al., 2004; Maertens et al., 2003;Priet et al., 2003; Turlure et al., 2004; Wiskerchen and Muesing,
1995). As these INs retained in vitro catalytic function
(Emiliani et al., 2005; Engelman and Craigie, 1992; Lu et al.,
2004; Priet et al., 2003) and when tested efficiently trans-
complemented the infectivity defect of class I IN active site
mutant viruses (Bouyac-Bertoia et al., 2001; Lu et al., 2004;
Priet et al., 2003), the results suggested that the IN-LEDGF/
p75 interaction could play an essential role in HIV-1 replication.
As the structure of the IBD-IN CCD complex was recently
solved (Cherepanov et al., 2005a), we used this information to
expand correlative analyses of host factor binding to IN and
HIV-1 function. Although our results indicate an overall trend of
parallel loss of LEDGF/p75-binding and HIV-1 infectivity with
minimal effects on IN catalytic function, some important excep-
tions were noted.
Previous studies revealed that replication-defective class I
mutants INQ62K and IND64N, as well as the INF185K class II
mutant protein, efficiently bound LEDGF/p75 as assessed by
Ni-NTA pull-down (Cherepanov et al., 2005b). In contrast, we
determined here that INA128Q, derived from a phenotypically
Fig. 4. In vitro IN assays. (A) Reaction scheme. IN cleaves the indicated
phosphodiester bond (vertical arrow), yielding a 3′ processing product that is
two bases shorter than substrate DNA. DNA strand transfer yields a
heterogeneous population of labeled products. The asterisk denotes the position
of 32P label. (B) Autoradiogram of reaction products. The migration positions of
substrate, 3′ processing, and DNA strand transfer reaction products are marked
21, 19, and ST, respectively. IN was omitted from the reaction in lane 1; the
remaining lanes contained the indicated IN protein. X, 20 base product most
likely generated by contaminating exonuclease III activity. (C) IN mutant 3′
processing activities. Error bars represent the variation obtained from a duplicate
set of assays; values were normalized to INWT activity. LKAA, L172A/K173A.
86 S. Rahman et al. / Virology 357 (2007) 79–90wild-type virus, failed to bind the host cell factor under these
conditions (Fig. 3A). As this and several other IN mutants
defective in the Ni-NTA pull-down assay displayed robust
interaction with LEDGF/p75 in a reciprocal GST-based assay(Fig. 3B), the latter design affords a more sensitive measure-
ment for the study of the IN-LEDGF/p75 interaction. Perhaps
dimerization of the GST moiety (Ji et al., 1992) allows GST-
IBD to engage two binding sites on an IN multimer in solution,
increasing overall affinity by increasing the avidity of the
protein–protein interaction. The results of GST pull-down
seemed to correlate well with the yeast two-hybrid assay, and
together these approaches afforded a comparison of approxi-
mate relative affinities of various IN mutant proteins. One
notable observation is that none of the studied mutations,
including V165A, R166A, and Q168A, completely abrogated
the IN-LEDGF/p75 interaction (Fig. 3D). Perhaps this fact
helps to explain why INV165A and INR166A proteins can
accumulate in the nuclei of transfected cells under conditions
of high IN expression (Limón et al., 2002). A similar
observation has been made with INH12N, in that it could be
“forced” to complex with LEDGF/p75 upon overexpression of
the host cell factor (Maertens et al., 2003).
Pleiotropic phenotypes of LEDGF/p75 interaction-defective
viruses
Though previous analyses of binding-defective IN proteins
were confined to replication-defective viruses, our structure-
based approach yielded mutants displaying a wide range of
infectivity phenotypes (Fig. 2). Two mutants in particular,
HIV-1W132D and HIV-1D167K, were partially defective. As the
DNA synthesis profiles of these viruses roughly mirrored their
infectious capacities (Figs. 2B and C), we infer that the single
round infectivity blocks in these cases is primarily at the step
of reverse transcription. Consistent with this interpretation,
HIV-1D167A and HIV-1D167K PICs isolated from acutely
infected cells each supported the wild-type level of in vitro
integration using a real-time PCR assay that normalizes DNA
strand transfer activity to the levels of endogenous cDNA
substrate made during reverse transcription (Lu et al., 2005c)
(data not shown). Given that each of the non-infectious mutants
synthesized significantly less cDNA than the wild-type (Fig.
2C), we categorize these as class II INmutant viruses (Engelman,
1999). This is consistent with our previous categorization of
HIV-1V165A as a class II mutant (Lu et al., 2004). Consistent with
the current classification, we note that Vpr-INQ168L, like pre-
viously characterized Vpr-INV165A (Lu et al., 2004) and
Vpr-INL172A/K173A (Priet et al., 2003), efficiently trans-com-
plemented the infectivity defect of class I IN active site HIV-1
(data not shown). Because the reverse transcription defects of
HIV-1E69R, HIV-1A129Q, HIV-1W132A, HIV-1V165A, HIV-1R166A,
HIV-1Q168A, HIV-1Q168L, and HIV-1L172A were approximately
2.5- to 15-fold (Fig. 2C) under conditions wherein infectivity
defects ranged from 125- to >10,000-fold (Fig. 2B; summarized
in Table 2), we emphasize that each of these mutant viruses is
predominantly blocked at the integration step of the HIV-1
lifecycle.
Only one of the novel mutant proteins, INW132A, was clearly
defective for in vitro integration activities (Figs. 4B and C). As
IND64N and INW132A were similarly inactive using a sensitive
real-time PCR assay to detect products of DNA strand transfer
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detected for INW132A (Fig. 4C) was most likely due to a
contaminating exonuclease activity in the INA129Q and INW132A
preparations (Fig. 4B).
Mechanism of LEDGF/p75-IN binding
It is important to note that the amino acid side-chains that
make direct LEDGF/p75-IN contacts in the IBD-CCD structure
are primarily donated from the host cell factor (Fig. 1). Thus,
mutation of LEDGF/p75 hotspot residue Asp-366 essentially
abrogates the protein–protein interaction under conditions
where single amino acid substitutions in IN merely reduce the
apparent affinity (Fig. 3D).
We have speculated that the phenotypes of LEDGF/p75-
binding defective INs are likely due to subtle losses of structural
integrity in and around the host factor binding cleft, and our
current results support this hypothesis. Thus, we infer that
disrupting the IN A chain R166-E69 intramolecular salt-bridge
via R166A or E69R changes, or the W132-Q168 intermolecular
H-bond via Q168L, Q168A, or W132A mutagenesis (Fig. 1),
subtly perturbs the IN dimer interface such that the apparent
affinity for LEDGF/p75 is lowered but in the majority of cases,
IN catalytic function is uncompromised. Likewise, altering
buried Val-165 to Ala likely disrupts the integrity of A chain α4
and the associated polypeptide backbone that connects α4 to
α5, where IN is directly contacted by IBD residue Asp-366
(Fig. 1) (Cherepanov et al., 2005a). On the other hand, we infer
that the A129Q mutation imparts a more severe structural affect
that negatively impacts IN solubility as well as LEDGF/p75
binding affinity. Though engineered to specifically clash with
LEDGF/p75 residue Ile-365, the Gln might predominantly
perturb the relatively intimate association between α1 and α3
(Fig. 1, leftward IN protomer).
The results of this study highlight that correlations of host
factor binding to HIV-1 fitness should be approached with
caution and would in all likelihood benefit from utilizing results
obtained from more than one protein–protein interaction assay.
This interpretation is highlighted by two of our current findings.
Firstly, INA128Q, which is derived from a phenotypically wild-
type virus, failed to detectably bind LEDGF/p75 by Ni-NTA
pull-down yet was efficiently recovered by the IBD in a GST
pull-down format (Figs. 3A and B). Secondly, GST-IBD
reproducibly recovered more input INQ168A, which is derived
from a replication-defective virus (Emiliani et al., 2005), than it
did the IN derived from phenotypically wild-type INH171A
(Figs. 2B and 3B). This latter observation highlights the
pleiotropic nature of many IN mutations. Considering this, we
speculate that the primary HIV-1Q168A replication defect is
unlikely the inability to bind LEDGF/p75. Although our results
allow us to conclude that in vitro protein binding is not a
universal indicator of IN mutant viral fitness, they fail to address
whether LEDGF/p75 plays a critical role in HIV-1 infectivity.
Despite this shortcoming, our findings highlight that subtle
alterations in the LEDGF/p75 binding region of the CCD dimer
interface in most cases impart catastrophic preintegration
defects on HIV-1 without grossly perturbing IN function.Thus, irrespective of LEDGF/p75 function, small molecules
designed to target the protein interaction interface might
similarly perturb preintegrative HIV-1 function. As several
groups are apparently targeting this region of IN for inhibitor
development (Al-Mawsawi et al., 2006; Cherepanov et al.,
2005a; Emiliani et al., 2005; Vandekerckhove et al., 2006),
understanding the molecular basis of its interaction with




Plasmids pKB-IN6H, pCP-Nat75 (Maertens et al., 2003),
pCP-GST75-81 (Cherepanov et al., 2004), and pCP-GST75-81/
D366N (Cherepanov et al., 2005b) were used to express IN-
His6, non-tagged LEDGF/p75, GST-tagged LEDGF
347–471, and
GST-LEDGF347–471/D366N in bacteria, respectively. Plasmids
pKB-IN6H and pUCWTpol (Limón et al., 2002) were modified
using QuikChange mutagenesis (Stratagene). Mutant pUCWT-
pol AgeI-PflMI fragments were swapped for the corresponding
wild-type fragments in pNL43/XmaI (Brown et al., 1999) and
pNLX.Luc(R−) (Lu et al., 2005b).
The bait plasmid pCPY414-DBD-IN encoding a fusion of
wild-type HIV-1NL4-3 IN to the DNA binding domain (DBD) of
GAL4 was constructed in the following way. The IN reading
frame amplified using primers 5′-GGCGCCATATGTTTTTA-
GATGGAATAGATAAGG and 5′-GGCGGAATTCC-
TAATCCTCATCCTGTCTACTTGCCAC was digested with
NdeI and EcoRI and subcloned between the NdeI and EcoRI
sites of pGBKT7 (Clontech). To avoid toxic effects associated
with overexpression of IN from the ADH1 promoter, the 1.1 kb
XhoI/EcoRI fragment of the resulting plasmid was ligated
between XhoI and EcoRI sites of pGBT9 (Clontech), placing
the GAL4 DBD-IN expression cassette under the control of a
deleted version of the ADH1 promoter. Finally, the 3 kb AfeI/
XbaI fragment carrying the promoter and GAL4-IN fusion was
subcloned between XbaI and SacII sites of the low copy vector
pRS414 (Sikorski and Hieter, 1989), yielding pCPY414-DBD-
IN. The prey construct, pCPY424-AD-IBD, expressing the
IBD (LEDGF326–471) fused to the activation domain (AD) of
GAL4, was constructed in two steps. First, an IBD-encoding
fragment amplified using primers 5′-GGCGCCATATGCAG-
CAGAATAAAGATGAAGG and 5′-GGCGGAATTCC-
TATTCCTTCTCTAGCTTTTTGTTTGGCC was digested
with NdeI and EcoRI and subcloned between NdeI and
EcoRI sites of pGADT7 (Clontech). To place the GAL4 AD-
IBD fusion under a weaker promoter, the 0.9 kb KpnI/XhoI
fragment of the resulting plasmid was subcloned between KpnI
and SalI sites of pGAD424 (Clontech), giving pCPY424-AD-
IBD. NdeI/EcoRI fragments of the bait and prey constructs
were replaced with mutagenized PCR-amplified fragments
encoding IN mutants V165A, R166A, Q168A, or L172A/
K173A or the LEDGF/p75 D366N mutation. All plasmid
constructs were sequenced and verified to be free of off-site
mutations.
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HIV-1NL4-3 IN carrying a C-terminal His6-tag was purified
from soluble extracts of E. coli strain BL21(DE3)pLysS
essentially as previously described (Cherepanov et al., 1997).
In brief, cells were lysed in 1 M NaCl, 7.5 mM [(3-
cholamidopropyl)-dimethylammonio]-l-propanesulfonate
(CHAPS)], 50 mM Tris–HCl (pH 7.4), and soluble IN was
enriched by batch absorption to Ni-NTA beads (QIAGEN).
Protein eluted in 200 mM imidazole, 1 M NaCl, 7.5 mM
CHAPS, and 50 mM Tris–HCl (pH 7.4) was diluted fourfold
with 50 mM Tris–HCl (pH 7.4) and 7.5 mM CHAPS prior to
injection into a 5-ml HiTrap Heparin column (Amersham
Biosciences). The protein was eluted using a linear 0.25 to 1 M
gradient of NaCl in 50 mM Tris–HCl (pH 7.4). Pooled fractions
were adjusted to 1 M NaCl, supplemented with 10 mM
dithiothreitol (DTT), 10% (wt/vol) glycerol, flash-frozen in
liquid nitrogen, and stored at −80 °C. Non-tagged LEDGF/p75,
GST-LEDGF347–471, and GST-LEDGF347–471/D366N were puri-
fied as previously described (Cherepanov et al., 2004, 2005b;
Maertens et al., 2003).
Protein interaction assays
Ni-NTA pull-down assays utilizing His6-tagged IN and GST
pull-downs using GST-LEDGF347–471 were performed as
described (Cherepanov et al., 2004, 2005b). Percent protein
recovery was quantified using Quantify One version 4.1.1
software (Bio-Rad Laboratories) and Coomassie-stained images
containing serial twofold dilutions of LEDGF/p75 or wild-type
IN (INWT) proteins.
Yeast two-hybrid interaction assays were done using
Saccharomyces cerevisiae strain Y187 containing the E. coli
lacZ gene under the control of GAL4-dependent upstream
activating sequences (Harper et al., 1993). Overnight cultures
of Y187 cells co-transformed with bait and prey GAL4
fusion constructs and grown in minimal Leu/Trp drop-out
medium were diluted fivefold with YPDA and incubated at
30 °C for 4 h with vigorous shaking. Cells were lysed in
YPER reagent (Pierce Biotechnology Inc.) for 15 min at
room temperature. Beta-galactosidase activity in cell lysates
measured using o-nitrophenyl-b-D-galactopyranoside substrate
was normalized to cell density (Reynolds et al., 2005). Four
independent colonies of co-transformed Y187 cells were
tested for each interaction pair.Cells, viruses, and infectivity assays
HeLa and 293T cells were cultured in Dulbecco's modified
Eagle's Medium supplemented to contain 10% fetal calf serum
(FCS), 100 IU/ml penicillin, and 0.1 mg/ml streptomycin
sulfate (DMEM). Jurkat T-cells were maintained in RPMI 1640
(RPMI) fortified with the same concentrations of FCS,
penicillin, and streptomycin. Viruses generated by transient
transfection were normalized for RT content as described
(Engelman et al., 1995; Lu et al., 2004).For single-round infectivity measurements, Jurkat cells (2×
106) were infected with 2×106 32P RT cpm of HIV-1NLX.Luc(R−)
(Lu et al., 2004) unless otherwise noted. Cultures were
maintained and processed for luciferase assays, and resultant
values were normalized to total cell protein, as described (Lu
et al., 2004). Results were corrected for background activities
derived from parallel infections conducted with envelope-
minus viruses.
For RQ-PCR assays, Jurkat cells (4×106) were infected
with 4×106 32P RT-cpm of DNase-treated virus as described
(Lu et al., 2004). Infected cells were washed, maintained in
RPMI, and harvested at 7 and 24 hpi also as described (Lu et
al., 2005b). LRT products were determined and normalized by
RQ-PCR as described (Limón et al., 2002); background values
obtained from parallel infections conducted with envelope-
minus viruses were subtracted from envelope-mediated values
as described (Lu et al., 2004).
In vitro enzyme assays
Manganese-dependent 3′ processing and DNA strand
transfer activities of recombinant IN proteins were determined
using a 21 bp mimic of the HIV-1 U5 end as previously
described (Lu et al., 2004). Phosphor screens exposed to wet
15% polyacrylamide denaturing gels were scanned using
Molecular Dynamics Scanner Control Version 4.1. Enzyme
activities were quantified as the percent of substrate converted
to product using ImageQuant version 1.2.Acknowledgments
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